Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia

This publication has 21 references indexed in Scilit:

• Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics
  Antimicrobial Agents and Chemotherapy, 1989
• Differences in drug susceptibility between isolates of pseudomonas cepacia recovered from patients with cystic fibrosis and other sources and its relationship to beta‐lactamase focusing pattern
  Pediatric Pulmonology, 1986
• In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum
  Antimicrobial Agents and Chemotherapy, 1985
• Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin
  Antimicrobial Agents and Chemotherapy, 1985
• In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin
  Antimicrobial Agents and Chemotherapy, 1984
• In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa
  Antimicrobial Agents and Chemotherapy, 1984
• In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis
  Antimicrobial Agents and Chemotherapy, 1984
• Pseudomonas cepacia infection in cystic fibrosis: An emerging problem
  The Journal of Pediatrics, 1984
• Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo
  The Journal of Infectious Diseases, 1983
• Synergy of Carbenicillin and Gentamicin in Experimental Infection with Pseudomonas
  The Journal of Infectious Diseases, 1971